Efficacy and tolerance of telaprevir in HIV-hepatitis C virus genotype 1-coinfected patients failing previous antihepatitis C virus therapy | Zendy

Karine Lacombe | Zendy; Nadia Valin | Zendy; H. Stitou | Zendy; Joël Gozlan | Zendy; Vincent Thibault | Zendy; Anders Boyd | Zendy; JeanMarie Poirier | Zendy; JeanLuc Meynard | Zendy; MarcAntoine Valantin | Zendy; Julie Bottero | Zendy; PierreMarie Girard | Zendy

Open Access

Efficacy and tolerance of telaprevir in HIV-hepatitis C virus genotype 1-coinfected patients failing previous antihepatitis C virus therapy

Author(s) -

Karine Lacombe,

Nadia Valin,

H. Stitou,

Joël Gozlan,

Vincent Thibault,

Anders Boyd,

JeanMarie Poirier,

JeanLuc Meynard,

MarcAntoine Valantin,

Julie Bottero,

PierreMarie Girard

Publication year - 2013

Publication title -

aids

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.195

H-Index - 216

eISSN - 1473-5571

pISSN - 0269-9370

DOI - 10.1097/qad.0b013e32836138d0

Subject(s) - telaprevir , ribavirin , medicine , pegylated interferon , hepatitis c virus , genotype , hepacivirus , hepatitis c , gastroenterology , virology , virus , biology , gene , biochemistry

The efficacy and tolerance of telaprevir (TVR) was examined in 20 mostly cirrhotic HIV-hepatitis C genotype 1 (HCV-G1)-infected patients failing previous treatment with pegylated-interferon and ribavirin (PR). HCV-RNA less than 12 IU/ml was observed in 35.3% of patients at W2, 55.0% at W4, 65.0% at W12 and 55.0% at W24. All patients with virological failure (n = 9) exhibited V36M/R155K mutations. Early virological response was a determinant of HCV-RNA less than 12 IU/ml at W24 (P < 0.001). No grade 3-4 dermatological side-effects were reported. TVR-PR tritherapy appeared to be rather effective and well tolerated among difficult-to-treat HIV-HCV-G1 patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research